CD8A and Miyoshi myopathy: While CAR‐T‐cell therapy has become an essential treatment for RRMM, addressing CAR‐T‐cell exhaustion remains a significant challenge.[2, 3] Building on our findings that the CD161–CLEC2D interaction induces CD8+ BM‐TRM dysfunction and promotes MM progression, we next determined whether CD161 is expressed on CAR‐T cells in RRMM patients and whether it contributes to their functional exhaustion.